FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Codon topics
Hydrocodone
Nucleic Acid
Acetaminophen
Carboxylic Acid
Benzoic Acid
Genetically
Recombinant
Amino Acid
Nucleotide
Reverse Transcriptase Inhibitors
Reverse Transcriptase Inhibitor
Reverse Transcriptase
Antibodies
Base Sequence
Replication

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Codon patents



      
           
This page is updated frequently with new Codon-related patents. Subscribe to the Codon RSS feed to automatically get the update: related Codon RSS feeds.

Subscribe to updates on this page: Codon RSS RSS

Date/App# patent app List of recent Codon-related patents
04/17/14
20140106401
 Selection of host cells expressing protein at high levels patent thumbnailnew patent Selection of host cells expressing protein at high levels
Described is a dna molecule comprising an open reading frame sequence encoding a selectable marker polypeptide, wherein the dna molecule in the coding strand comprises a translation start sequence for the selectable marker polypeptide having a gtg or ttg start codon, and wherein the orf sequence that encodes the selectable marker protein has been mutated to replace at least half of its cpg dinucleotides as compared to the native orf sequence that encodes the selectable marker protein. Further provided are such dna molecules wherein the orf sequence that encodes a selectable marker polypeptide is part of a multicistronic transcription unit that further comprises an open reading frame sequence encoding a polypeptide of interest.
04/10/14
20140099338
 Yeast expressed classical swine fever virus glycoprotein e2 and use thereof patent thumbnailYeast expressed classical swine fever virus glycoprotein e2 and use thereof
The present invention provides a recombinant yeast system for expressing the glycoprotein e2 of classical swine fever virus (csfv), in which the expression level of ye2 is improved by codon optimization and shortening coding region of e2 gene. The truncated e2 subunits are used as major active ingredient in anti-csfv vaccines and useful diagnostic blocking elisa kits for csfv infection with easy manipulation and low cost..
04/03/14
20140094457
 Pharmaceutical compositions and treatment of genetic diseases associated with nonsense mediated rna decay patent thumbnailPharmaceutical compositions and treatment of genetic diseases associated with nonsense mediated rna decay
The present invention relates to pharmaceutical compositions comprising a compound and a pharmaceutically acceptable carrier. The present invention is also directed to a method of treating a genetic disease caused by premature termination codons, or other conditions that render messenger ribonucleic acid (mrna) susceptible to nonsense mediated rna decay, in a subject.
04/03/14
20140093942
 Gene, ars-r anchorage cassette, ars-r expression-anchorage cassette, recombinant plasmid, bacterial transgenic lineage, use of said gene, use of said lineage in environmental bioremediation processes patent thumbnailGene, ars-r anchorage cassette, ars-r expression-anchorage cassette, recombinant plasmid, bacterial transgenic lineage, use of said gene, use of said lineage in environmental bioremediation processes
The present invention relates to the construction and insertion of a dna plasmid vector of broad spectrum for gram-negative bacteria, that carries a gene sequence which, when expressed, enables the anchorage of a chelator protein for arsenic ions on the gram-negative bacteria cellular surface. For that end, the structural sequence of the regulatory arsr gene without stop codon (seq id no 1) was amplified by polymerase chain reaction (pcr) using as a template the chromosome 1 of cupriavidus metallidurans, ch34 lineage and inserted into the pgem-t cloning vector, yielding the pgemt-as plasmid (seq id no 2).
03/27/14
20140087402
 Synthetic luciferase gene and protein patent thumbnailSynthetic luciferase gene and protein
A codon optimized and stabilized luciferase gene and a novel recombinant dna characterized by incorporating this new gene coding for a novel luciferase into a vector dna for improved activities in mammalian cells, are disclosed. This new luciferase exhibits long-wavelength light emission, as well as improved thermostability and higher expression levels in mammalian cell systems, compared to native luciferase.
03/27/14
20140086951
 Pharmaceutical composition and methods for modulating immune system, preventing, pretreating and/or treating cancers patent thumbnailPharmaceutical composition and methods for modulating immune system, preventing, pretreating and/or treating cancers
This invention provides a pharmaceutical composition for modulating immune system comprising at least one polysaccharide extracted from radix astragali, radix codonopsis, ganoderma sinense, or mixtures thereof, and their extraction process. The present invention further relates to a method of modulating immune system by applying said pharmaceutical composition to a subject suffering from cancers, and a method of preventing and/or pretreating and/or treating cancers in the subject, where said method comprises applying said pharmaceutical composition before/during chemotherapy..
03/20/14
20140082760
 Non-human animals expressing ph-sensitive immunoglobulin sequences patent thumbnailNon-human animals expressing ph-sensitive immunoglobulin sequences
Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a hisidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence. Immunoglobulin genes comprising histidines in one or more cdrs, in an n-terminal region, and or in a loop 4 region are also provided.
03/20/14
20140079731
 Sin nombre virus full-length m segment-based dna vaccines patent thumbnailSin nombre virus full-length m segment-based dna vaccines
The invention contemplates a new synthetic, codon-optimized sin nombre virus (snv) full-length m gene open reading frame (orf) that encodes a unique consensus amino acid sequence. The snv orf was cloned into a plasmid to form the first stable recombinant snv full-length m gene that elicits neutralizing antibodies.
02/20/14
20140051170
 Process, vectors and engineered cell lines for enhanced large-scale transfection patent thumbnailProcess, vectors and engineered cell lines for enhanced large-scale transfection
Processes, vectors and engineered cell lines for large-scale transfection and protein production in mammalian cells, especially chinese hamster ovary (cho) cells are described in which transfection efficiencies are realized through the use of a single vector system, the use of functional orip sequences in all plasmids, the use of codon-optimized epstein-barr virus nuclear antigen-1 (ebna1) constructs, the use of a fusion protein between a truncated epstein-barr virus nuclear antigen-1c (ebna1c) protein and a herpes simplex virus protein vp16, the use of a 40 kda fully deacetylated poly(ethylenimine) as a transfection reagent, the use of co-expression of a fibroblast growth factor (fgf) and/or the use of protein kinase b to potentiate heterologous gene expression enhancement by valproic acid (vpa).. .
02/13/14
20140045877
 Pharmaceutical preparation containing oxycodone and naloxone patent thumbnailPharmaceutical preparation containing oxycodone and naloxone
The invention concerns a storage stable pharmaceutical preparation comprising oxycodone and naloxone for use in pain therapy, with the active compounds being released from the preparation in a sustained, invariant and independent manner.. .
02/13/14
20140045876
Process
The present invention provides a process for preparing an oxycodone acid adduct, said process comprising hydrogenating an aqueous solution of 14-hydroxycodeinone and an acid to form a solution of the oxycodone acid adduct, wherein the hydrogenation is carried out at one or more temperatures greater than ambient temperature in the presence of a hydrogenation catalyst and hydrogen gas, wherein the solution of oxycodone acid adduct comprises 6α-oxycodol in an amount ≦about 0.800 area % as determined by hplc.. .
02/13/14
20140045261
Site-specific incorporation of amino acids into molecules
The invention provides certain embodiments relating to methods and compositions for incorporating non-natural amino acids into a polypeptide or protein by utilizing a mutant or modified aminoacyl-trna synthetase to charge the non-natural amino acid to a the corresponding trna. In certain embodiments, the trna is also modified such that the complex forms strict watson-crick base-pairing with a codon that normally forms wobble base-pairing with unmodified trna/aminoacyl-trna synthetase pairs..
02/13/14
20140044782
Controlled release formulations of opioid and nonopioid analgesics
Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic.
02/06/14
20140038286
Codon optimized sodium-iodide symporter gene and its use
The present disclosure provides a polynucleotide which is codon optimized for the efficient expression in a eukaryotic cell, a plasmid and a eukaryotic cell comprising the same. The modification resulted in the efficient expression of nis in eukaryotic cells and the enhancement of the function of nis by glycosylation.
01/30/14
20140031382
Dosage form containing oxycodone and naloxone
The present invention concerns a dosage form comprising oxycodone and naloxone which is characterized by specific in vivo parameters such as tmax, cmax, auct value, mean bowel function score and/or duration of analgesic efficacy.. .
01/30/14
20140030707
Small rna-dependent translational regulatory system in cell or artificial cell model
An object of the present invention is to construct an mrna which specifically responds to a short rna sequence and can activate, repress, and regulate the translation of the desired gene, and to construct an artificial cell model system using a liposome comprising the mrna and a cell-free translational system encapsulated therein. The present invention provides: an mrna comprising a target rna-binding site located immediately 5′ to the ribosome-binding site, and a nucleotide sequence located 5′ to the target rna-binding site, the nucleotide sequence being complementary to the ribosome-binding site; an mrna comprising a small rna-binding site located 3′ to the start codon, and a nucleotide sequence located 3′ to the small rna-binding site, the nucleotide sequence encoding a protein; and a liposome comprising any of these mrnas encapsulated therein..
01/23/14
20140024806
Glycoproteins produced in plants and methods of their use
Methods of increasing the yield in plant expression of recombinant proteins comprising engineering glycosylation sites into cloned genes or cdnas for proteins using codons that drive post-translational modifications in plants; and engineering the cloned genes or cdnas to contain a plant secretory signal sequence that targets the gene products (protein) for secretion. The methods result in increased recombinant glycosylated protein yields.
01/16/14
20140018257
Peptide library production method, peptide library, and screening method
Object is to provide a method of constructing a library of peptides having, at a desired position in the random sequence of each peptide, an amino acid having a portion capable of binding to a target. The invention provides a method of producing a library of peptides having, at a designated position in the random sequence of each peptide, a special amino acid having a portion capable of binding to a target, including (i) preparing a library of mrnas having, in the mrna sequence coding for a random amino acid sequence, a base sequence having an altered codon encoding the special amino acid, (ii) preparing an aminoacyl trna with the special amino acid linked to a trna encoded by the altered codon, and (iii) translating the mrnas by using a cell-free translation system containing the aminoacyl trna to obtain a library of peptides having, in the random sequence thereof, a predetermined special amino acid..
01/16/14
20140017259
Immunotherapy against erbb-3 receptor
The present invention describes methods and pharmaceutical compositions for the treatment of cancer in mammals, more particularly in human subjects. More specifically, the invention concerns anti-tumor vaccines based upon plasmid dna and/or genetic vectors carrying a codon-usage optimized sequence and coding for a mutant form of the erbb-3 receptor.
01/09/14
20140013456
Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of ph dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses human immunoglobulin light chain variable domains derived from a limited repertoire of human immunoglobulin light chain variable gene segments that comprise histidine modifications in their germline sequence.
01/09/14
20140011262
Methods for producing secreted polypeptides
The present invention relates to methods for producing a polypeptide, comprising: (a) cultivating a fungal host cell in a medium conducive for the production of the polypeptide, wherein the fungal host cell comprises a nucleic acid construct comprising a first nucleotide sequence encoding a signal peptide operably linked to a second nucleotide sequence encoding the polypeptide, wherein the first nucleotide sequence is foreign to the second nucleotide sequence and the 3′ end of the first nucleotide sequence is immediately upstream of the initiator codon of the second nucleotide sequence. The present invention also relates to the isolated signal peptide sequences and to constructs, vectors, and fungal host cells comprising the signal peptide sequences operably linked to nucleotide sequences encoding polypeptides..
01/09/14
20140011235
Release factor 1 (rf1) in escherichia coli
Provided herein are release factor 1 (rf1) deficient bacteria, methods of using the bacteria to reassign the uag codon, and generate mutant polypeptides.. .
12/26/13
20130344565
Optimization of expression and purification of recombinant human mxa protein in e. coli
Full length mxa constructs and truncated mxa constructs produce human mxa protein in e. Coli.
12/26/13
20130344143
Formulations of nonopioid and confined opioid analgesics
The preferred exemplary embodiments in the present application provide formulations and methods for the delivery of drugs, particularly drugs of abuse, having an abuse-relevant drug substantially confined in the core and a non-abuse relevant drug in a non-core region. These formulations have reduced potential for abuse.
12/19/13
20130338043
Efficient, expansive, user-defined dna mutagenesis
The presently disclosed subject matter provides methods for the creation of one or more user-defined mutations that can be located anywhere in a target sequence, such as in a gene. These mutations can comprise single mutations, multiple mutations, or a comprehensive codon mutagenesis library, in which all possible single codon substitutions in a gene are created.
12/12/13
20130331558
Nucleotide sequences mutated by insertion that encode a truncated oleate desaturase protein, proteins, methods and uses
Isolated nucleotide sequences mutated by insertion encoding a truncated sunflower oleate desaturase protein, truncated protein, methods, procedures and uses. The isolated nucleotide sequences comprise an insertion that includes a stop codon, and wherein the sequences encode a truncated sunflower oleate desaturase protein.
12/05/13
20130323275
Methods and compositions for inducing a t-cell response to plasmodium species
The present invention relates to methods of inducing a t-cell response against a plasmodium species antigen in a subject. These method comprise administering to a subject a composition comprising a bacterium which expresses one or more immunogenic polypeptides, the amino acid sequence of which comprise one or more amino acid sequences derived from wild-type plasmodium lsa1, ce1tos, csp, and/or trap sequences, wherein said amino acid sequences are derived by (i) codon optimization of the wild-type sequence for expression in said bacterium, (ii) deletion of at least one hydrophobic region present in the wild-type sequence, and/or (iii) in the case of lsa1 and csp, minimization of repeat units present in the wild-type sequence..
11/14/13
20130302418
Controlled release hydrocodone formulations
A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
11/07/13
20130296532
Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav
The present invention relates nucleic acid constructs for the production of recombinant parvoviral (e.g. Adeno-associated viral) vectors in insect cells, to insect cells comprising such constructs and to methods wherein the cells are used to produce recombinant parvoviral virions.
11/07/13
20130295177
Controlled release hydrocodone
A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
10/31/13
20130289091
Antisense antibacterial method and compound
A method and antisense compound for inhibiting the growth of pathogenic bacterial cells are disclosed. The compound contains no more than 12 nucleotide bases and has a targeting nucleic acid sequence of no fewer than 10 bases in length that is complementary to a target sequence containing or within 10 bases, in a downstream direction, of the translational start codon of a bacterial mrna that encodes a bacterial protein essential for bacterial replication.
10/24/13
20130281667
Uses of spatial configuration to modulate protein function
This invention provides a set of methods for modulating protein spatial configuration. First, select the amino-acid codon for encoding the target protein according to host codon usage.
10/24/13
20130281479
Sustained release monoeximic formulations of opioid and nonopioid analgesics
The present invention relates to monoeximic solid dosage forms for administering pharmaceutical agents, particularly hydrocodone and acetaminophen, methods for preparing said dosage forms, and methods for providing therapeutic agents to patients in need of treatment.. .
10/17/13
20130274283
Premature-termination-codons readthrough compounds
Premature termination codons readthrough compounds, composition thereof, and methods of making and using the same are provided.. .
10/17/13
20130274276
Methods and compositions for determining virus susceptibility to non-nucleoside reverse transcriptase inhibitors
Methods and compositions for the efficient and accurate determination of hiv susceptibility to a non-nucleoside reverse transcriptase inhibitor (nnrti) are provided. In certain aspects, the methods involve detecting in a biological sample a nucleic acid encoding an hiv reverse transcriptase that comprises a mutation at codon 188, wherein the presence of the reverse transcriptase-encoding nucleic acid in the biological sample indicates that the hiv has a decreased susceptibility to an nnrti.
10/17/13
20130273170
Puumala virus full-length m segment-based dna vaccines
The invention contemplates a new synthetic, codon-optimized puumala virus (puuv) full-length m gene open reading frame (orf) that encodes a unique consensus amino acid sequence. The puuv orf was cloned into a plasmid to form the first stable puuv full-length m gene that elicits neutralizing antibodies.
10/03/13
20130261259
Genetically encoded initiator for polymer growth from proteins
This invention pertains to methods for producing homogeneous recombinant proteins that contain polymer initiators at defined sites. The unnatural amino acid, 4-(2′-bromoisobutyramido)phenylalanine of formula 1, was designed and synthesized as a molecule comprising a functional group further comprising an initiator for an atom-transfer radical polymerization (‘atrp”) that additionally would provide a stable linkage between the protein and growing polymer.
10/03/13
20130259909
Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology..
09/26/13
20130252994
Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology..
09/19/13
20130247236
Non-human animals expressing ph-sensitive immunoglobulin sequences
Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a hisidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence. Immunoglobulin genes comprising histidines in one or more cdrs, in an n-terminal region, and or in a loop 4 region are also provided.
09/19/13
20130247235
Mice that produce antigen-binding proteins with ph-dependent binding characteristics
Genetically modified non-human animals are provided that comprise an immunoglobulin heavy chain locus comprising an unrearranged human heavy chain variable region nucleotide sequence comprising an addition of at least one histidine codon or a substitution of at least one endogenous non-histidine codon with a histidine codon. Compositions and methods for making the genetically modified non-human animals as described herein are provided.
09/19/13
20130247234
Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of ph dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses a single light chain variable domain derived from a single rearranged light chain variable region gene in the germline of the non-human animal, wherein the single rearranged light chain variable region gene comprises a substitution of at least one non-histidine encoding codon with a histidine encoding codon.
09/19/13
20130245265
Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology..
09/19/13
20130245054
Use of binders for manufacturing storage stable formulations
The present invention relates to storage stable prolonged release pharmaceutical dosage forms comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof, the manufacture thereof as well as their use for administration to human beings.. .
09/19/13
20130244964
Novel hiv-1 reverse transcriptase codon deletion and its use in the management and treatment of hiv infections
The present invention provides an isolated hiv-1 mutant and isolated nucleic acid molecules comprising hiv-rt coding sequences harboring a novel mutation in the s68 codon, and in particular, deletions of the s68 codon. This novel deletion reduces the sensitivity of hiv to various nucleoside reverse transcriptase inhibitors.
09/05/13
20130230888
Heterologous expression of fungal cellobiohydrolase 2 genes in yeast
The present invention provides for heterologous expression of polypeptides encoded by wild-type and codon-optimized cbh2 genes from the organisms cochliobolus heterostrophus, gibberella zeae, irpex lacteus, volvariella volvacea, and piromyces sp. In host cells, such as the yeast saccharomyces cerevisiae.
08/29/13
20130225795
Recombinant codon optimised factor h
The present invention relates to recombinant factor h and variants and conjugates thereof and methods of their production, as well as uses and methods of treatment involving the materials.. .
08/22/13
20130217599
Novel artificial translation/synthesis system
A new artificial translation-synthesis system of adding trnas binding special amino acids to the in vitro translation system and synthesizing peptides with special amino acids incorporated thereto according to a dual genetic code table and an artificial codon box division.. .
08/22/13
20130217072
Heterologous expression of fungal cellobiohydrolase 2 genes in yeast
The present invention provides for heterologous expression of polypeptides encoded by wild-type and codon-optimized cbh2 genes from the organisms cochliobolus heterostrophus, gibberella zeae, irpex lacteus, volvariella volvacea, and piromyces sp. In host cells, such as the yeast saccharomyces cerevisiae.
08/22/13
20130217020
Methods for improving sensitivity and specificity of screening assays of kras codons 12 and 13 mutations
A method of diagnosing a kras gene mutation at codons 12-13 in a dna sample is disclosed. The method comprises detecting one or more than one mutation in the kras gene codons 12-13 of the dna sample by performing an allelic discrimination assay using a mutant probe, a wild-type probe paired with the mutant probe, a forward primer and a reverse primer, the mutant probe being adapted to detect a single nucleotide mutation at 1a, 1t, 1c, 2a, 2t, 2c or 5a of the kras gene codons 12-13 of the dna sample, and the primers each having no greater than 25 nucleotides in length are adapted to amplify a region spanning kras exon 2 codons 12-13, wherein the mutant and wild-type probes are labeled with different fluorescent dyes..


Popular terms: [SEARCH]

Codon topics: Hydrocodone, Nucleic Acid, Acetaminophen, Carboxylic Acid, Benzoic Acid, Genetically, Recombinant, Amino Acid, Nucleotide, Reverse Transcriptase Inhibitors, Reverse Transcriptase Inhibitor, Reverse Transcriptase, Antibodies, Base Sequence, Replication

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patents related to Codon for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Codon with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.2269

3027

2 - 1 - 71